SG49625A1 - Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions - Google Patents

Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Info

Publication number
SG49625A1
SG49625A1 SG1996001470A SG1996001470A SG49625A1 SG 49625 A1 SG49625 A1 SG 49625A1 SG 1996001470 A SG1996001470 A SG 1996001470A SG 1996001470 A SG1996001470 A SG 1996001470A SG 49625 A1 SG49625 A1 SG 49625A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical compositions
compositions
neuroprotective pharmaceutical
effective
dexanabinol derivatives
Prior art date
Application number
SG1996001470A
Other languages
English (en)
Inventor
Raphael Mechoulam
Emil Pop
Mordechai Sokolovsky
Original Assignee
Univ Ramot
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Yissum Res Dev Co filed Critical Univ Ramot
Publication of SG49625A1 publication Critical patent/SG49625A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
SG1996001470A 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions SG49625A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals

Publications (1)

Publication Number Publication Date
SG49625A1 true SG49625A1 (en) 1998-06-15

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001470A SG49625A1 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Country Status (10)

Country Link
US (1) US5521215A (enExample)
EP (1) EP0765160B1 (enExample)
JP (1) JPH09511493A (enExample)
AT (1) ATE237324T1 (enExample)
AU (1) AU690221B2 (enExample)
CA (1) CA2183466A1 (enExample)
DE (1) DE69530389T2 (enExample)
IL (1) IL112572A0 (enExample)
SG (1) SG49625A1 (enExample)
WO (1) WO1995020958A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
TR199901173T2 (xx) 1996-09-27 1999-07-21 Guilford Pharmaceuticals, Inc. Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
CA2288693A1 (en) * 1997-05-07 1998-11-12 Unimed Pharmaceuticals, Inc. Method of improving disturbed behavior and elevating mood in humans
CA2295098A1 (en) * 1997-06-30 1999-01-07 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
DE69936640D1 (de) * 1998-04-21 2007-09-06 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
JP2003511469A (ja) 1999-10-18 2003-03-25 ユニバーシティ オブ コネチカット 抹消カンナビノイド受容体（ｃｂ２）選択的配位子
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
NZ522349A (en) * 2000-06-22 2004-06-25 Pharmos Corp Non-psychotropic cannabinoids that afford neuroprotection by exhibiting anti-inflammatory and/or antioxidative and glutamate-receptor blocking mechanisms of action
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
AU2002309548B2 (en) * 2001-04-06 2006-08-10 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep
CA2452881C (en) * 2001-07-13 2012-03-06 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
CA2464333C (en) * 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003256059A1 (en) * 2002-09-05 2004-03-29 Pharmos Corporation Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
CN101316832A (zh) 2005-09-29 2008-12-03 Amr科技公司 δ-9-四氢大麻酚的生成方法
MX2010001242A (es) * 2007-07-30 2010-07-02 Alltranz Inc Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
EP3188734A4 (en) 2014-09-02 2018-01-10 The Texas A&M University System Method of treating organophosphate intoxication
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
EP3654942A1 (en) 2017-07-20 2020-05-27 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法
WO2019106652A1 (en) 2017-11-29 2019-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
CA3116194A1 (en) 2018-11-04 2020-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Orally administrable cannabinoids-containing compositions and methods
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1995020958A1 (en) 1995-08-10
DE69530389T2 (de) 2004-03-25
ATE237324T1 (de) 2003-05-15
AU1743395A (en) 1995-08-21
EP0765160B1 (en) 2003-04-16
CA2183466A1 (en) 1995-08-10
DE69530389D1 (de) 2003-05-22
IL112572A0 (en) 1995-05-26
JPH09511493A (ja) 1997-11-18
EP0765160A1 (en) 1997-04-02
AU690221B2 (en) 1998-04-23
US5521215A (en) 1996-05-28
EP0765160A4 (enExample) 1997-04-09

Similar Documents

Publication Publication Date Title
SG49625A1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
EP1299374A4 (en) NEW NON PSYCHOTROPICAL CANNABINOIDS
BG101118A (en) Therapeutical compounds
IL115245A0 (en) Tumor necrosis factor inhibiting pharmaceuticals
SI0725779T1 (enExample)
TW362973B (en) Use of 2-anino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a composition having an antidepressant activity
MX9708800A (es) Compuestos biciclicos aromaticos.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
CA2243404A1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
AU2030497A (en) Propynyl or dienyl biaromatic compounds
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP1785417A3 (en) Novel non-psychotropic cannabinoids
MXPA02003731A (es) Derivados novedosos de acido fusidico.
AU2626392A (en) Use of substituted pyrrolidines, some of which are known, as medicaments, new active substances and processes for their preparation
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
MX9708385A (es) Derivados novedosos de tetraciclina, composiciones que los contienen, y el uso de las mismas.